|
|||||
|
|
| 伊立替康联合奈达铂二线治疗晚期食管鳞癌24例 | |
| 引用本文： | 刘莺,梁冰,刘文静,王居峰,樊青霞.伊立替康联合奈达铂二线治疗晚期食管鳞癌24例[J].世界华人消化杂志,2010,18(3). |
| 作者姓名： | 刘莺 梁冰 刘文静 王居峰 樊青霞 |
| 作者单位： | 1. 河南省肿瘤医院内科,河南省郑州市,450003 2. 郑州大学第二附属医院肿瘤科,河南省郑州市,450014 3. 郑州大学第一附属医院肿瘤科,河南省郑州市,450052 |
| 摘 要： | 目的:观察伊立替康(CPT-11)联合奈达铂(NDP)二线治疗晚期食管鳞癌的疗效及不良反应.方法:依照开放原则,24例经组织学证实的食管鳞状细胞癌患者一线化疗疾病进展(PD)者,按CPT-11 65 mg/m2在第1-8天1h内静脉输注,然后NDP 80 mg/m2第12 h内静脉输注,21 d为1周期.每化疗2周期后按RECIST标准评价疗效,每1周期后根据CTCAE3.0进行不良反应分级.所有患者随访24 mo,结果采3用KaplanMeier进行生存分析.结果:24例均可评价疗效,完全缓解(CR)1例(4%),部分缓解(PR)5例(21%),稳定(SD)7例(29%),PD 11例(46%),有效率25%(CR+PR),疾病控制率54%(CR+PR+SD);中位生存时间(OS)248.5 d(95%CI:159-563 d),中位至疾病进展时间(TTP)131 d(95%CI:45-382 d).3级血液学毒性:贫血1例(4%),中性粒细胞减少4例(17%),白细胞减少5例(21%),血小板减少1例(4%).仅有1例4级中性粒细胞减少,研究中未观察到3-4级非血液学毒性,无治疗相关性死亡.结论:伊立替康联合奈达铂二线治疗晚期食管鳞癌的近期疗效显著,不良反应轻,耐受性好. |
| 关 键 词： | 伊立替康 奈达铂 二线治疗 食管鳞癌 |
Combined chemotherapy with irinotecan and nedaplatin as a second-line regimen for patients with advanced esophageal squamous cell carcinoma:a report of 24 cases |
|
| Ying Liu,Bing Liang,Wen-Jing Liu,Ju-Feng Wang,Qing-Xia Fan.Combined chemotherapy with irinotecan and nedaplatin as a second-line regimen for patients with advanced esophageal squamous cell carcinoma:a report of 24 cases[J].World Chinese Journal of Digestology,2010,18(3). | |
| Authors: | Ying Liu Bing Liang Wen-Jing Liu Ju-Feng Wang Qing-Xia Fan |
| Institution: | Ying-Liu,Wen-Jing Liu,Ju-Feng Wang,Department of Internal Medicine,Henan Provincial Tumor Hospital,Zhengzhou 450003,Henan Province,China Bing-Liang,Department of Oncology,the Second Affiliated Hospital of Zhengzhou University,Zhengzhou 450014,China Qing-Xia Fan,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China |
| Abstract: | AIM:To evaluate the efficacy and safety of combined chemotherapy with irinotecan and nedaplatin as a second-line regimen for advanced esophageal cancer.METHODS:An open trial was performed.Twenty-four patients with histopathologically confirmed esophageal squamous cell carcinoma who received combination chemotherapy with irinotecan and nedaplatin as a second-line regi-men were evaluated.The combination therapy consisted of intravenous administration of irinotecan 65 mg/m 2 over 1 hour on days 1 and 8 of a 21... |
| Keywords: | Irinotecan Nedaplatin Second-line chemotherapy Esophageal squamous cell carcinoma |
| 本文献已被 CNKI 万方数据 等数据库收录！ | |